Effects of metformin withdrawal after long and short term treatment in PCOS: observational longitudinal study
Open Access
- 12 April 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetology & Metabolic Syndrome
- Vol. 13 (1), 1-9
- https://doi.org/10.1186/s13098-021-00660-5
Abstract
Metformin plays a consolidated role in the management of polycystic ovary syndrome (PCOS). However, there is no clear answer on how long we should treat and on how long its beneficial impact sustain after we stop treatment. We compared the effects of metformin withdrawal after long-term (LT) and short term (ST) treatment in PCOS women that had previously well responded to metformin. We conducted observational longitudinal study including 44 PCOS women (31 (28–36) years and BMI 32.5 (27.7–34.9) kg/m2) that were followed for 6 months after metformin withdrawal. Prior inclusion, ST group had been treated with metformin on average for 1.03 ± 0.13 year, LT group for 5.07 ± 2.52 years. We followed anthropometric, metabolic, reproductive parameters and eating behavior as assessed by TFEQ-R18. After metformin withdrawal, ST group gained significant amount of weight (from 92 (75.5–107.3) kg to 96 (76–116) kg; p = 0.019). Weight tended to increase also in LT users (from 87 (75–103) to 87 (73–105) kg; p = 0.058). More women in LT group maintained stable weight (27% in LT group vs 15% in ST group). Eating behavior deteriorated in both groups. Withdrawal of metformin resulted in a decrease of menstrual frequency (6 (6–6) to 6 (4–6) menstrual bleeds per 6 months; p = 0.027) and in borderline increase of androstenedione (6.4 (4.6–7.6) to 7.8 (4.8–9.6) nmol/L; p = 0.053) in LT group. Waist circumference, HOMA and glucose homeostasis remained stable in both groups. There were no differences between groups at 6-month follow up. Collectively, present study implies some metabolic and endocrine treatment legacy in both groups as well as some group-specific deteriorations in clinical parameters 6 months after metformin withdrawal. Trial registration: The study is registered at Clinical Trials with reference No. NCT04566718Keywords
Funding Information
- Javna Agencija za Raziskovalno Dejavnost RS (#P3-0298)
This publication has 29 references indexed in Scilit:
- Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes StudyDiabetes Care, 2012
- Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndromeActa Endocrinologica, 2010
- Alteration of ghrelin–neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinismClinical Endocrinology, 2008
- Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: A retrospective analysisEndocrine Practice, 2007
- Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndromeMetabolism, 2006
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)Human Reproduction, 2004
- Follow-up Report on the Diagnosis of Diabetes MellitusDiabetes Care, 2003
- Decreases in Ovarian Cytochrome P450c17α Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary SyndromeThe New England Journal of Medicine, 1996
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985
- The three-factor eating questionnaire to measure dietary restraint, disinhibition and hungerJournal of Psychosomatic Research, 1985